Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Indivior Pharmaceuticals Inc (INDV)

Indivior Pharmaceuticals Inc (INDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Indivior Pharmaceuticals Inc 10710 Midlothian Turnpike Suite 125 North Chesterfield VA 23235 USA

www.indivior.com Employees: 1,051 P: 804-379-1040

Sector:

Medical

Description:

Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 4,431,959
Enterprise Value, $K 4,445,959
Shares Outstanding, K 125,020
Float, K 125,020
% Float 100.00%
Short Interest, K 11,696
Short Float 9.36%
Days to Cover 5.44
Short Volume Ratio 0.40
% of Institutional Shareholders 60.33%

Financials:

Annual Sales, $ 1,188 M
Annual Net Income, $ 2,000 K
Last Quarter Sales, $ 314,000 K
Last Quarter Net Income, $ 42,000 K
EBIT, $ 277,000 K
EBITDA, $ 306,000 K

Growth:

1-Year Return 203.51%
3-Year Return 46.00%
5-Year Return 421.32%
5-Year Revenue Growth 51.34%
5-Year Earnings Growth 44.35%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.72 on 10/30/25
Next Earnings Date 02/26/26 [BMO]
Earnings Per Share ttm 1.96
EPS Growth vs. Prev Qtr 41.18%
EPS Growth vs. Prev Year 33.33%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 10/11/22

INDV Ratios

Ratio
Price/Earnings ttm 17.86
Price/Earnings forward 12.10
Price/Earnings to Growth N/A
Return-on-Equity % -90.79%
Return-on-Assets % 17.91%
Profit Margin % 0.17%
Debt/Equity -1.56
Price/Sales 3.84
Price/Cash Flow 19.23
Price/Book N/A
Book Value/Share 0.00
Interest Coverage -1.34
60-Month Beta 0.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar